Customization: | Available |
---|---|
Application: | Internal Medicine |
Usage Mode: | For oral administration |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
1)Acute myelogenous leukemia: Daunorubicin hydrochloride alone or in combination with other approved anticancer drugs is indicated for remission induction in acute myelogenous leukemia and for remission induction in promyelocytic leukemia.
2)Acute lymphocytic leukemia: Daunorubicin hydrochloride has a high remission rate for the treatment of acute lymphocytic leukemia, but because of its serious side effects and there are other effective therapeutic methods available, it is only applied to those cases that have become resistant to other drugs. Co-administration of daunorubicin hydrochloride with prednisone and vincristine has been proven to be very successful in the acute phase of acute lymphocytic leukemia.
3)Other tumors: Daunorubicin showed a good effect on the treatment of neuroblastoma and rhabdomyosarcoma.
Detailed Photos
Company Profile
Our Advantages
The group built up a long technology partnership with more than 100 institutes and universities at home and abroad meanwhile it enhances its own independent innovation system. Lunan Enterprise Technology center's technology innovative ability ranks the forefront in Pharmaceutical industry and got the title"Top Ten Best Industrial Enterprises of Domestic Pharmaceutical R & D Product Line".